An acquisition last year by a Pacific Northwest biotech company has paid off, in the form of a successful registration-directed breast cancer study. The company – which is based in the suburb of ...

-Collaboration Combines Seattle Genetics’ Expertise in Cancer Targets and Antibody-Based Therapies with Unum’s Novel Antibody-Coupled T-cell Receptor (ACTR) Technology- -Companies to Focus on the ...

The field of human genetics and genomics research has seen spectacular progress and advances in human health and well-being that are nothing short of remarkable. In just a few years, we have been able ...

The Food and Drug Administration is imposing a clinical hold on several of Seattle Genetics’ early-stage studies involving an experimental cancer drug following the deaths of four people, Reuters ...

Clay Siegall is the founder and CEO of Seattle Genetics. Anthony Bolante | PSBJ To continue reading this content, please enable JavaScript in your browser settings ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS ...

Fintel reports that Capital International Investors has filed a 13G/A form with the SEC disclosing ownership of 18.06MM shares of Seattle Genetics, Inc. (SGEN). This represents 9.7% of the company. In ...

LOS ANGELES, Sept 24 (Reuters) - Biotechnology company Seattle Genetics will announce on Monday results from a pivotal trial of experimental drug brentuximab vedotin in patients with Hodgkin lymphoma.

Seattle Genetics and Bayer HealthCare will collaborate on developing new antibody-drug conjugates (ADCs). Bayer is paying up-front and option exercise fees of up to $20 million for rights to use ...

* Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors Sign up here. * Seattle Genetics Inc - planned ...